HempFusion Announces Large-Scale Distribution Agreement with Fullscript.com to Launch Doctor Practitioner Sales Channel
21.1.2021 15:01:00 EET | Business Wire | Press release
HempFusion Wellness Inc. (TSX:CBD.U) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that it has entered into a large-scale distribution agreement with Fullscript.com (“Fullscript”), a leading eCommerce platform that allows health professionals to dispense professional-grade natural health products. Fullscript is one of the largest distributors in the category, providing nutritional supplements to over 80,000 practitioners and over 600,000 patients across the United States and Canada.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005282/en/
Total Care Daily Probiotic from Biome Research (Photo: Business Wire)
This agreement signifies HempFusion’s strategic launch into the doctor practitioner sales channel.
HempFusion’s seven Biome Research SKUs will be available to ship from Fullscript distribution centers starting February 2, 2021.
“We are incredibly excited to launch doctor practitioner sales starting with Biome Research, a specialized wholly-owned HempFusion brand designed specifically for doctors, practitioners and their patients,” stated Nancy Angelini, HempFusion’s Director of Doctor/Practitioner.
“An industry-leading eCommerce platform like Fullscript, with a deep and established distribution network, is a tremendous advantage to HempFusion. We expect this channel to drive significant revenue growth for the Company,” continued Angelini.
Biome Research products have been under development by the Company for nearly 14 months. The products include scientifically documented strains of beneficial and living probiotic bacteria that utilize an exclusive and scientifically validated MAKTrek 3-D Probiotic Delivery System. All formulations are based on well-founded scientific research using validated methods to protect and deliver live probiotics to the lower gastrointestinal tract. The launch concludes many months of planning and preparation, including procurement of the product ingredients, final SKU productions and logistics.
“The launch into the doctor practitioner sales channel is crucial. It is a major component of the Company’s broader five-channel distribution strategy, which includes planned expansion in Natural, eCommerce, Food & Drug Mass, and Convenience channels,” stated Jason Mitchell, N.D, HempFusion’s Chief Executive Officer.
Biome Research is a division of HempFusion’s wholly-owned subsidiary, Probulin Probiotics, LLC.
ABOUT FULLSCRIPT
Fullscript is an online dispensary platform designed by Healthy Web Inc. that allows health professionals to dispense the industry’s largest catalogue of professional-grade natural health products.
ABOUT HEMPFUSION
HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retail locations across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 46 SKUs including tinctures, proprietary FDA Drug Listed Over-The-Counter (OTC) Topicals, Doctor/Practitioner Lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable, and HempFusion’s wholly-owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex™ and are available in-store or by visiting HempFusion online at www.hempfusion.com or www.probulin.com.
Follow HempFusion on Twitter, Facebook and Instagram and Probulin on Twitter, Facebook and Instagram.
FORWARD-LOOKING STATEMENTS
This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, “forward-looking statements“) that relate to HempFusion’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result”, “are expected to”, “expects”, “will continue”, “is anticipated”, “anticipates”, “believes”, “estimated”, “intends”, “plans”, “forecast”, “projection”, “strategy”, “objective” and “outlook”) are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward-looking statements relating to the Company’s launch into the doctor practitioner sales channel, revenue growth, planned expansion in Natural, e-Commerce, Food Drug Mass and Convenience sales channels and the Company’s other plans, focus and objectives.
Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond HempFusion’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID-19 pandemic and other factors set forth under “Forward-Looking Statements” and “Risk Factors” in the final long form prospectus of the Company dated December 17, 2020 and available under the Company’s profile on SEDAR at www.sedar.com. HempFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for HempFusion to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210121005282/en/
Contact information
Jason Mitchell, N.D.
Chief Executive Officer and Director
Email: ir@hempfusion.com
Phone: 416-803-5638
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gurobi's Research Leadership Recognized Across Leading Scientific Organizations16.6.2026 16:00:00 EEST | Press release
Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced recognitions received by Dr. Edward Rothberg and Dr. Andreas Wächter from leading academic and industry organizations for research that has had lasting impact on the field of optimization. “Gurobi was founded on a commitment to rigorous, applied optimization research,” said Dr. Oliver Bastert, CTO, Gurobi. “And these recognitions are a reflection of that legacy. The foundational work that Ed and Andreas produced continues to shape the field, and that same spirit of scientific innovation drives everything we do today.” Dr. Edward Rothberg, co-founder and Chairman of the Board at Gurobi, was recently honored with the INFORMS Test of Time Paper Award for his paper, “An Evolutionary Algorithm for Polishing Mixed Integer Programming Solutions.” The paper introduced a novel approach to finding high-quality solutions to difficult MIP problems — expanding what was possible within the MIP framework and inf
New CSC Report Illustrates How AI Is Affecting Enterprise Security Leaders16.6.2026 16:00:00 EEST | Press release
CSC, an enterprise-class domain registrar and world leader in mitigating brand, fraud, domain, and domain name system (DNS) threats, today released new research on how chief information security officers (CISOs) are adapting to an evolving artificial intelligence (AI) ecosystem while managing traditional cyber threats, such as DNS outages. According to CSC’s CISO Outlook 2026 report, 73% of respondents say AI presents more of an opportunity than a risk for cybersecurity. However, these security leaders continue to face challenges in addressing attacks, including AI-powered domain generation algorithms (DGAs), which 86% of respondents cite as a threat. To thoroughly understand the CISO perspective on today’s cybersecurity landscape, CSC surveyed 300 senior executives—including CISOs, chief technology officers (CTOs), chief information officers (CIOs), and heads of cybersecurity—in Q1 2026. Key findings from the CISO Outlook 2026 report include: Respondents ranked the top three threats i
Airship Helps DIE ZEIT Turn Silent Advocates into 4.9-Star Rating16.6.2026 16:00:00 EEST | Press release
Airship, the mobile-first customer experience company, today announced that DIE ZEIT, one of Germany’s largest and most prestigious publishers, has successfully transformed its mobile app presence, lifting the Google Play app store rating from 2.7 stars in early 2026 to a near-perfect 4.9 stars. At a time when many traditional publishers are seeing readership numbers plummet, DIE ZEIT is growing — reaching an all-time high circulation in 2025 and building a digital ecosystem around the brand. The majority of the publication’s readers are now digital, but the publication’s app store rating for DIE ZEIT didn’t match this momentum. DIE ZEIT was up against a universal challenge faced by digital product teams and customer experience executives globally: the "silent advocate" problem. While highly satisfied customers rarely pause their reading experience to leave public reviews, users facing temporary, one-off frustrations are highly motivated to voice complaints. This discrepancy often lead
Clearlake Capital Closes on $14.8 Billion to Capitalize on AI-Driven Transformation and Continue Sector-Focused Investment Strategy16.6.2026 16:00:00 EEST | Press release
Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced the successful close of its eighth flagship fund, Clearlake Capital Partners VIII (“Fund VIII”), alongside related co-investment vehicles and separately managed accounts. Together, these vehicles represent $14.8 billion of capital commitments and position Clearlake to continue investing behind the secular trends reshaping industries, including artificial intelligence, software modernization, digital transformation, and operational efficiency. The successful fundraise comes amid a highly competitive and selective fundraising environment for private markets and underscores continued investor confidence in Clearlake's differentiated sector-focused strategy, integrated investment platform, and proven ability to create value across market cycles. The close was supported by a diverse
TestMu AI Introduces DevTools Assertions in Kane CLI, Enabling Browser-Level Validation Through Natural Language16.6.2026 15:30:00 EEST | Press release
TestMu AI (formerly LambdaTest), the world's first Agentic AI-powered Quality Engineering platform, today announced DevTools Assertions for Kane CLI, enabling developers and AI agents to validate browser internals using natural language. Traditional browser automation focuses on what users can see: buttons, forms, text, and visual states. However, modern web applications depend heavily on browser activity that remains invisible to users, including network requests, API responses, console logs, cookies, local storage, and performance metrics. With DevTools Assertions, Kane CLI extends browser validation beyond the UI, allowing teams to verify these underlying signals using plain-English objectives. Developers can now write objectives such as: "Click Add to Cart and assert the request to /api/cart returned status 200." "Run the checkout flow and assert the console has no errors." "Log in and store the session cookie value." "Assert localStorage contains the selected product ID." "Open th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom